National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic evaluation of Rivaroxaban (Xarelto®) for the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.

Rapid Review

Commenced Completed Outcome
17/08/2011 31/08/2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
28/11/2011 24/02/2012 Cost effective at submitted price

We consider that at the submitted price Rivaroxaban could be considered cost-effective for this indication.

 Rivaroxaban (Xarelto®) for DVT summary